Uploaded January 2026 | Updated September 2026, 3 days ago
At the EASD 2025 Annual Meeting in Vienna, the SURPASS-CVOT trial results were revealed, providing crucial insights for the management of type 2 diabetes. In this EASD TV interview, Prof. Tina Vilsbøll (EASD Honorary Secretary) and Prof. Hertzel Gerstein (EASD-Independent Advisor and McMaster University) discuss the trial outcomes, their significance for clinical practice, and the future of personalized medicine in diabetes care.
Key takeaways:
- Comparative efficacy: tirzepatide (15 mg weekly) was found non-inferior to dulaglutide (1.5 mg weekly) in reducing major cardiovascular events (MACE: MI, stroke, cardiovascular death).
- Patient-centred impact: This trial emphasises therapies that improve both metabolic control and cardiovascular outcomes, benefiting patients directly.
- Large-scale evidence: Over 13,000 participants make this the second largest and longest cardiovascular outcomes trial for diabetes.
- Transdisciplinary approach: Collaboration between diabetologists, cardiologists, nephrologists, and neurologists is shaping future research and guideline development.
- Personalised medicine: The results add another layer to tailor treatment strategies based on patient-specific needs and risk profiles.
This interview highlights how teaching, research, and outcomes trials are transforming diabetes care beyond glucose control, providing therapies that truly matter to patients.
At the EASD 2025 Annual Meeting in Vienna, the SURPASS-CVOT trial results were revealed, providing crucial insights for the management of type 2 diabetes. In this EASD TV interview, Prof. Tina Vilsbøll (EASD Honorary Secretary) and Prof. Hertzel Gerstein (EASD-Independent Advisor and McMaster University) discuss the trial outcomes, their significance for clinical practice, and the future of personalized medicine in diabetes care.
Key takeaways:
- Comparative efficacy: tirzepatide (15 mg weekly) was found non-inferior to dulaglutide (1.5 mg weekly) in reducing major cardiovascular events (MACE: MI, stroke, cardiovascular death).
- Patient-centred impact: This trial emphasises therapies that improve both metabolic control and cardiovascular outcomes, benefiting patients directly.
- Large-scale evidence: Over 13,000 participants make this the second largest and longest cardiovascular outcomes trial for diabetes.
- Transdisciplinary approach: Collaboration between diabetologists, cardiologists, nephrologists, and neurologists is shaping future research and guideline development.
- Personalised medicine: The results add another layer to tailor treatment strategies based on patient-specific needs and risk profiles.
This interview highlights how teaching, research, and outcomes trials are transforming diabetes care beyond glucose control, providing therapies that truly matter to patients.
